

# Capturing Feature-Level Irregularity in Disease Progression Modeling

Kaiping Zheng, Wei Wang, Jinyang Gao, Kee Yuan Ngiam,  
Beng Chin Ooi, Wei Luen James Yip

Presenter: Kaiping Zheng  
Nov 9<sup>th</sup>, 2017



# Outline

- **Introduction**
- **Existing Solutions for Irregularity**
- **Problem Definition**
- **Methodology**
- **Evaluation**
- **Case Study**
- **Conclusion**

# Introduction

## ***Chronic Diseases***


- Major cause of illnesses and deaths
- Likely to worsen with more severe comorbidities and complications without intervention

## ***Disease Progression Modeling (DPM)***

- Employ computational methods to model the progression of a target disease
- Facilitate early detection and treatment of chronic diseases before deterioration
- Exploit electronic medical records (EMR) for analytics

# Introduction

## Electronic Medical Records (EMR)




# Introduction

## *Electronic Medical Records (EMR)*

- One major challenge of DPM over EMR data is on handling the **irregularity** issue of the time series EMR data
- Two levels: visit-level irregularity, feature-level irregularity
  - Visit-Level Irregularity
    - EMR data appears irregularly with time
    - Time span between consecutive visits is irregular
  - Feature-Level Irregularity
    - Same feature appears irregularly in EMR data with time
    - Time span between a feature's consecutive occurrences is irregular

# Introduction

## Electronic Medical Records (EMR)



# Outline

- Introduction
- **Existing Solutions for Irregularity**
- Problem Definition
- Methodology
- Evaluation
- Case Study
- Conclusion

# Existing Solutions for Irregularity

## I. **Converting to Non-Time Series Data**

(Duchesne et al., 2009; Stonnington et al., 2010; Zhou et al., 2011; Zhou et al., 2012)

- ☺ simple computation and modeling
- ☹ under-utilization of time series EMR data

## II. **Transforming into Regular Time Series Data**

### - Dynamic Bayesian networks or variant graphical models

(Van Gerven et al., 2008; Exarchos et al., 2013; Wang et al., 2014)

- ☺ causality and interpretability
- ☹ time-consuming & need experts' domain knowledge

### - Deep learning models

(Che et al., 2014; Che et al., 2015; Lipton et al., 2016)

- ☺ better performance in many areas for feature learning
- ☹ difficult to capture feature patterns within a time window



# Existing Solutions for Irregularity


## III. Without Transforming Data

- Input EMR data of patients' visits in chronological order without considering the intrinsic irregularity (Choi et al., 2016)
- Utilize irregular EMR data by concatenating the visits' timestamps in the inputs (Choi et al., 2016)
- Use the time span as a visit-level decay term to analyze EMR data (Pham et al., 2016)
  - ☺ incorporate all visit-level information available
  - ☹ not use feature-wise time span or distinguish various features

# Outline

- Introduction
- Existing Solutions for Irregularity
- **Problem Definition**
- Methodology
- Evaluation
- Case Study
- Conclusion

# Problem Definition



## Disease Progression Modeling (DPM)


Given a set of training samples  $\{ \langle x, y, \Delta t \rangle \}$ , the objective of DPM is to obtain a mapping function  $\Phi$  that minimizes the following loss function over all samples:

$$L(\Phi(x, \Delta t), y)$$

# Outline

- Introduction
- Existing Solutions for Irregularity
- Problem Definition
- **Methodology**
- Evaluation
- Case Study
- Conclusion

# Methodology




Medical Feature Input ( $x^{(t)}$ : EMR Data)

**Loss function:** 
$$L = \frac{1}{|\{\langle x, y, \Delta t \rangle\}|} \sum (y^{(n)} - y)^2$$

**Back-propagation algorithm for updating the model parameters**

# Methodology



**Compute a decay term  $\varrho$  using  $\tau(t)$  and multiply  $\varrho$  to  $z(t)$**

- $\varrho = 1 - \tanh(W_\tau \tau^{(t)} + b_\tau)$
- $z(t) = \text{sigmoid} \left( (W_z x^{(t)} + U_z h^{(t-1)}) \odot \varrho \right)$

# Outline

- Introduction
- Existing Solutions for Irregularity
- Problem Definition
- Methodology
- **Evaluation**
- Case Study
- Conclusion

# Evaluation

## ***ADNI dataset***

- Public Alzheimer's disease dataset from Alzheimer's Disease Neuroimaging Initiative
- Severity is measured by Mini-Mental State Examination (MMSE) test ( $\in [0,30]$ )

## ***NUH-CKD dataset***

- Extract from a chronic kidney disease (CKD) dataset from National University Hospital in Singapore
- Choose patients with Stage 3 CKD or higher as cohort, "NUH-CKD" dataset
- Severity is measured by Glomerular Filtration Rate (GFR) test ( $\in [0,60]$ )

## ***Evaluation metrics***

- Mean squared error (MSE)
- Pearson product-moment correlation coefficient (R) value



# Evaluation

Dataset	ADNI1 Dataset	NUH-CKD Dataset
# of medical features	591	603
# of demo. features	3 – age, gender, education time	2 – age, gender
# of patients	819	2740
Time span	4 years, M00 to M48, (“M” – “month”)	1 year, W00 to W52, (“W” – “week”)
# of time steps	7 (aggregated by every 6 months)	52 (aggregated by every week)
CutPoint ( $t_\psi$ ) setting	M12, M18, M24	W16, W24, W32
# of samples	$t_\psi = \text{M12}$ : 1529 $t_\psi = \text{M18}$ : 1200 $t_\psi = \text{M24}$ : 558	$t_\psi = \text{W16}$ : 3601 $t_\psi = \text{W24}$ : 2793 $t_\psi = \text{W32}$ : 1585

# Evaluation

## ***GRU-based baselines***

- Window-Based Model
- Visit-Level Model
- Visit-Level Time Decay Model

## ***Multi-task learning (MTL) methods*** (Zhou et al., 2012)

- Least Convex Fused Group Lasso (cFSGL)
- Least Non-Convex Fused Group Lasso (nFSGL), denote two formulations as nFSGL-1 and nFSGL-2 in experiments

## ***Our proposed method***

- Feature-Level Time Decay Model

# Evaluation




Figure: Experimental results in the ADNI dataset

- For the same CutPoint setting, from Window-Based Model to Feature-Level Time Decay Model, performance is mainly on the ascending trend; Feature-Level Time Decay Model more accurate than MTL-based methods;
- When CutPoint becomes larger, MSE values of GRU-based models decrease

# Evaluation




Figure: Experimental results in the NUH-CKD dataset

- From W16 to W24, GRU-based models achieve larger MSE values - **decreasing number of samples**
- From W24 to W32, GRU-based models achieve smaller MSE values - **more time series features**
- Both the sample length and sample number affect the model performance

# Outline

- **Introduction**
- **Existing Solutions for Irregularity**
- **Problem Definition**
- **Methodology**
- **Evaluation**
- **Case Study**
- **Conclusion**

# Case Study – Patient I




Figure: Disease progression modeling illustration for representative CKD Patient I in the NUH-CKD dataset

## Severe and deteriorating

- GFR decreases in the first 32 weeks and drops to around 35
- From the 32nd week, GFR remains in the descending trend
- Furthermore, our proposed model predicts that as time further goes on, the loss of Patient I's GFR will exceed  $5\text{ml}/\text{min}/1.73\text{m}^2$  within one year
- Our model would suggest Patient I to consult specialists for expert assessment

# Case Study – Patient2




Figure: Disease progression modeling illustration for representative CKD Patient2 in the NUH-CKD dataset

## Mild yet deteriorating

- In the beginning, GFR indicates only moderately reduced kidney function. However, GFR decreases slowly over time before the 52nd week
- After the 52nd week, our model predicts that the patient will suffer from a large drop in GFR, indicating the deterioration of kidney functioning
- **Our model would suggest healthcare workers to provide more aggressive interventions to Patient2 in advance**

# Case Study – Patient3




Figure: Disease progression modeling illustration for representative CKD Patient3 in the NUH-CKD dataset

## Severe yet stable

- Patient3 is already in CKD Stage5 in the beginning
- Through the whole year, this patient progresses stably without much change in GFR
- Our model gives the prediction that this stableness will maintain for a long time
- Our model would suggest guaranteeing the monitoring for Patient3



# Outline

- **Introduction**
- **Existing Solutions for Irregularity**
- **Problem Definition**
- **Methodology**
- **Evaluation**
- **Case Study**
- **Conclusion**

# Conclusion

- I. Identify the irregularity characteristic residing in EMR data both at the visit level and at the feature level***
  
- II. Capturing feature-level irregularity can benefit EMR data analytics through Feature-Level Time Decay Model***
  - Handle feature-level irregularity
  - Decay the influence of previous information on patients' current state
  - Learn decaying parameters for different features
  
- III. Evaluate proposed Feature-Level Time Decay Model in both a public ADNI dataset and a private NUH-CKD dataset for two chronic disease cohorts***

**Thank you!**

